Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
18.31
-0.10 (-0.54%)
Jun 18, 2026, 4:00 PM EDT - Market closed

Monte Rosa Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
1,5471,028427283375950
Market Cap Growth
445.50%140.76%50.68%-24.53%-60.50%-
Enterprise Value
919.66689.8197.4396.92159.53604.19
Last Close Price
18.3115.686.945.657.6120.42
PS Ratio
36.018.315.64---
PB Ratio
2.964.411.911.581.382.73
P/TBV Ratio
3.055.592.301.621.321.47
P/FCF Ratio
--11.23---
P/OCF Ratio
--10.16---
EV/Sales Ratio
21.415.581.29---
EV/FCF Ratio
--2.56---
Debt / Equity Ratio
0.070.150.170.240.160
Debt / FCF Ratio
--1.12---
Net Debt / Equity Ratio
-1.20-1.45-1.48-1.04-0.79-1.00
Net Debt / EBITDA Ratio
4.487.374.511.361.994.89
Net Debt / FCF Ratio
31.9112.29-8.672.972.055.01
Asset Turnover
0.070.280.20000
Quick Ratio
9.446.052.375.0010.5820.80
Current Ratio
9.546.122.405.0710.7920.96
Return on Equity (ROE)
-34.44%-16.94%-36.15%-60.07%-35.06%-40.35%
Return on Assets (ROA)
-24.67%-11.88%-22.65%-44.47%-31.71%-35.06%
Return on Invested Capital (ROIC)
-157.30%-38.80%-62.14%-181.85%-257.49%-337.96%
Return on Capital Employed (ROCE)
-28.25%-16.27%-30.10%-49.94%-33.72%-39.42%
FCF Yield
--8.90%---
Buyback Yield / Dilution
-9.92%-12.40%-43.80%-8.83%-88.91%-1548.09%
Total Shareholder Return
-9.92%-12.40%-43.80%-8.83%-88.91%-1548.09%
SEC Filings: 10-K · 10-Q